DNIB0600A
DNIB0600A Uses, Dosage, Side Effects, Food Interaction and all others data.
DNIB0600A is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
| Trade Name | DNIB0600A |
| Generic | Lifastuzumab vedotin |
| Lifastuzumab vedotin Other Names | DNIB0600A, Lifastuzumab vedotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here DNIB0600A
